Why is this medication prescribed?
Jelmyto (mitomycin) is prescribed for the treatment of a specific type of cancer called low-grade upper tract urothelial cancer (UTUC). UTUC refers to cancer that develops in the lining of the upper urinary tract, including the ureters (tubes that connect the kidneys to the bladder) and the renal pelvis (the central part of the kidney where urine collects before entering the ureters).
Jelmyto is specifically indicated for the treatment of low-grade UTUC tumors that are non-invasive or have minimal invasion into the surrounding tissues. It is used when the cancer is localized to the urinary tract and has not spread to other parts of the body.
The medication works by damaging the DNA in cancer cells, which helps to inhibit their growth and division. By directly applying Jelmyto to the affected area of the urinary tract, it can target the cancer cells and potentially reduce or eliminate the tumor.
How should this medicine be used?
Jelmyto (mitomycin) is administered through a procedure called pyelocalyceal solution, which involves the direct instillation of the medication into the urinary tract. The following are general guidelines for the use of Jelmyto, but it’s important to note that specific dosing and administration instructions should be provided by a healthcare professional and may vary depending on the individual’s condition:
- Procedure: The administration of Jelmyto is typically performed by a healthcare provider. It involves the placement of a ureteral catheter into the affected kidney through a scope called a ureteroscope.
- Instillation: Once the ureteral catheter is in place, Jelmyto is instilled directly into the renal pelvis, which is the central part of the kidney where urine collects before entering the ureters. The medication is introduced into the urinary tract through the catheter.
- Absorption and Retention: After instillation, the ureteral catheter is typically left in place for a specific period of time, allowing the medication to be absorbed by the tumor cells. The duration of catheter retention will be determined by the healthcare provider.
- Follow-up: Regular monitoring and follow-up appointments will be necessary to assess the response to treatment and determine the need for further instillations or additional interventions.
It’s important to adhere to the instructions provided by your healthcare provider regarding the dosing, administration, and follow-up schedule for Jelmyto. They will provide you with detailed guidance based on your specific condition and treatment plan.
Other uses for this medicine
Jelmyto (generic name: mitomycin) is a medication used specifically for the treatment of low-grade upper tract urothelial cancer (UTUC), a type of cancer that affects the lining of the urinary tract. Its primary use is as an intravesical chemotherapy agent, meaning it is directly instilled into the urinary system to target cancer cells.
What special precautions should I follow?
When using Jelmyto for the treatment of low-grade upper tract urothelial cancer (LG-UTUC), there are several precautions you should follow:
- Medical supervision: Jelmyto should only be administered under the supervision of a healthcare professional experienced in the use of this medication. They will guide you through the treatment process and monitor your progress.
- Inform your healthcare provider: It is crucial to inform your healthcare provider about any pre-existing medical conditions, allergies, or medications you are currently taking. This information will help them determine if Jelmyto is suitable for you and if any adjustments need to be made.
- Follow the treatment schedule: Stick to the prescribed treatment schedule as directed by your healthcare provider. Do not skip or delay any doses without consulting them first.
- Hydration: It is important to maintain adequate hydration during the treatment period. Drink plenty of fluids as recommended by your healthcare provider to help flush out the medication and minimize potential side effects.
- Follow-up appointments: Attend all follow-up appointments scheduled by your healthcare provider. They will monitor your response to the treatment, conduct necessary tests, and adjust the treatment plan if needed.
- Side effect management: Jelmyto may cause certain side effects such as urinary tract infections, blood in the urine, pain or discomfort in the treatment area, and urinary frequency or urgency. Report any concerning symptoms to your healthcare provider promptly, as they can provide appropriate guidance and support.
Remember, these precautions are general guidelines, and it is important to consult your healthcare provider for personalized advice based on your specific situation and medical history.
What special dietary instructions should I follow?
Jelmyto is a medication used for the treatment of low-grade upper tract urothelial cancer (LG-UTUC). It is delivered directly into the kidney through a procedure called pyelocalyceal instillation. Since Jelmyto is administered locally, it does not require specific dietary instructions. However, it is always best to consult with your healthcare provider or follow any specific guidelines they provide.
What should I do if I forget a dose?
If you forget a dose of Jelmyto, it is important to contact your healthcare provider or medical team as soon as possible. They will be able to provide you with the appropriate guidance on how to proceed. It is generally not recommended to administer a double dose or to make up for a missed dose without consulting your healthcare provider first. They may suggest rescheduling the missed dose or adjusting the treatment plan accordingly.
What side effects can this medication cause?
Jelmyto (mitomycin) is a medication used for the treatment of low-grade upper tract urothelial cancer (UTUC), a type of cancer that affects the lining of the urinary tract. Like any medication, Jelmyto can cause side effects. The most common side effects associated with Jelmyto include:
- Urinary tract infection: Symptoms may include pain or burning during urination, frequent urination, urgency to urinate, and cloudy or bloody urine.
- Hematuria: This refers to blood in the urine, which may appear pink, red, or brown.
- Fatigue: Feeling tired or weak.
- Nausea: A feeling of sickness or queasiness, sometimes accompanied by vomiting.
- Abdominal pain: Discomfort or pain in the stomach area.
- Vomiting: The act of forcefully expelling the stomach’s contents through the mouth.
- Renal impairment: Problems with kidney function, which may manifest as changes in urine output, increased thirst, swelling, or changes in blood test results.
- Hydronephrosis: The swelling of a kidney due to a build-up of urine, which can cause pain or discomfort in the lower back or sides.
- Dysuria: Pain or discomfort during urination.
- Pyrexia: A fever, characterized by an elevated body temperature.
It’s important to note that these side effects are not exhaustive, and other less common or rare side effects may occur. If you are prescribed Jelmyto and experience any concerning or persistent side effects, it’s essential to inform your healthcare provider for further evaluation and guidance.
What should I know about storage and disposal of this medication?
- Storage of Jelmyto:
- Keep Jelmyto vials refrigerated at a temperature between 2°C and 8°C (36°F and 46°F).
- Do not freeze the medication.
- Protect the vials from light by keeping them in the original carton until ready for use.
- Keep Jelmyto out of the reach of children and pets.
- Disposal of Jelmyto:
- Dispose of Jelmyto in accordance with local regulations or guidelines.
- If you have unused or expired Jelmyto, consult with your healthcare provider, local pharmacy, or waste disposal agency on the proper disposal method.
In case of emergency/overdose
- In case of an emergency or overdose, contact your healthcare provider, local emergency services, or go to the nearest emergency room immediately.
- It is helpful to take the original packaging or container of Jelmyto with you to provide relevant information to medical professionals.
What other information should I know?
- Jelmyto is administered by a healthcare professional as a liquid directly into the kidney or upper urinary tract through a procedure called retrograde pyelography.
- It is important to inform your healthcare provider about any allergies, medical conditions, or medications you are currently taking before starting Jelmyto.
- Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding, as the use of Jelmyto in these situations should be discussed.
- Jelmyto can cause side effects, including but not limited to urinary tract infection, blood in the urine, pain or burning during urination, and fatigue. Contact your doctor if you experience any adverse reactions.
Remember, this information is a general guideline, and it’s important to consult with your healthcare provider or pharmacist for specific instructions and guidance on the storage, disposal, and management of Jelmyto.
